Validation of right ventricular endomyocardial biopsy as a surrogate marker of left ventricular fibrosis in dilated cardiomyopathy

Validation of right ventricular endomyocardial biopsy as a surrogate marker of left ventricular fibrosis in dilated cardiomyopathy - Biopsy as a surrogate maker for left ventricular fibrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049998

Enrollment

100

Registered

2023-01-11

Start date

2021-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dilated cardiomyopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have had pathological evaluation performed in the Pathology Department of our institution. 2) For autopsy cases, patients who had a right ventricular endocardial biopsy performed prior to death. 3) For heart transplant cases, patients who have undergone right ventricular endocardial biopsy prior to transplantation.

Exclusion criteria

Exclusion criteria: 1) Patients with coronary artery disease, previous cardiac surgery (excluding assistive device implantation including LVAD), or apparent acute myocarditis. 2) Patients who have declared non-participation in the study after reading the opt-out document. 3) Patients who are deemed inappropriate by the Principal Investigator or the Principal Investigator.

Design outcomes

Primary

Measure	Time frame
Association of right ventricular (RV) endocardial myocardial biopsy (EMB) histopathology with the degree of left ventricular (LV) fibrosis in explanted hearts that subsequently underwent pathologic dissection or heart transplantation.	—

Countries

Japan

Contacts

Public ContactKisaki Amemiya

National Cerebral and Cardiovascular Center Department of Pathology

amemiya.kisaki@ncvc.go.jp+81-(6)6-6170-1070

Outcome results